A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Summary

This study will evaluate the safety and tolerability of multiple doses of LY2127399 (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment period. All participants will be followed for up to 12 weeks after the last study drug administration.

Timeline

Start

2009-09

Primary completion

2011-08

Completion

2011-08

Drugs

Indications